The Foundation for the National Institutes of Health Honors Longstanding Partners Richard J. Hodes, M.D., and Eli Lilly & Company with Charles A. Sanders, M.D., Partnership Award

BETHESDA, MD, September 20, 2017 — The Foundation for the National Institutes of Health (FNIH) is proud to recognize Richard J. Hodes, M.D., Director of the National Institute on Aging (NIA), an institute of the National Institutes of Health (NIH), and Eli Lilly & Company (Lilly) as recipients of the second annual Charles A. Sanders, M.D., Partnership Award. Named for former Chairman of the FNIH Board Dr. Charles Sanders, the award honors persons and/or organizations that have made significant contributions to the FNIH’s work to build, implement and nurture private-public partnerships in support of the mission of the NIH. Through their longstanding work with the FNIH over more than a decade, Dr. Hodes and Lilly have advanced trailblazing biomedical research in critical disease areas, including age-related disorders such as Alzheimer’s disease, and helped structure innovative public-private partnerships.

“We are pleased to recognize two outstanding partners that helped create and lead keystone programs at the FNIH and, in turn, develop new models for public-private alliances in biomedical research,” said Steven M. Paul, M.D., Chairman of the FNIH Board. “For their unwavering commitment and leadership in biomedical research, we are proud to present the second annual Charles A. Sanders, M.D., Partnership Award to Dr. Richard Hodes and Lilly.”

Named Director of the NIA in 1993, Dr. Hodes is one of the FNIH’s earliest and most significant partners at the NIH, exemplifying what a proactive government leader can do to advance science through public-private partnerships. NIA currently collaborates with the FNIH on 11 projects, including the groundbreaking Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Hodes was instrumental in developing the governance structure and open-access data policy of this first-of-its-kind partnership that brought together the scientific expertise and resources from the public and private sectors to uncover the biological markers that track Alzheimer’s disease progression. ADNI paved the way for other public-private partnerships, such as the trailblazing Accelerating Medicines Partnership (AMP), which united the NIH and the FNIH with the private sector to transform the model for developing new diagnostics and treatments in multiple disease areas. Dr. Hodes plays an active leadership role in AMP by serving on the Executive Committee of the AMP Alzheimer’s Disease (AMP-AD) initiative and has invested $25 million from the NIA in this program.

“I am pleased that this award recognizes the partnerships that we have been able to bring together, focusing on frailty in aging and on Alzheimer’s and related dementias research,” noted Dr. Hodes. “These partnerships join the considerable scientific talent and resources supported by NIH with those in the private sector, and the synergy created through these efforts has been quite impressive. Most importantly, they are resulting in meaningful scientific progress toward treatment or even prevention of conditions that can so deeply affect the lives of older people and their families.”

From osteoporosis to lung cancer to autism, Lilly has advanced critical research with the FNIH in several disease areas—contributing more than $25 million and supporting 44 projects since 2000. Lilly played a critical role in ADNI’s establishment, becoming the first company to join the partnership and championing support from other industry representatives. Lilly also supports projects within the FNIH Biomarkers Consortium focused on colorectal cancer and diabetes, among others, and is a significant proponent of AMP, contributing to the AMP-AD and the AMP Type 2 Diabetes projects. In particular, Lilly leadership help guide the overall direction of AMP by serving on its Executive Committee and on the Steering Committees of AMP-AD and the AMP Type 2 Diabetes initiative.
“Public-private partnerships involving the biopharmaceutical industry, NIH and academia have advanced key areas of human disease understanding and the potential for diagnostics and therapies by unifying resources and capabilities and making findings public,” said Jan Lundberg, PhD., executive vice president, science and technology, and president, Lilly Research Laboratories. “The data from these joint efforts are now guiding our evolving strategy for clinical trials in Alzheimer’s disease which should benefit patients and their caregivers. Lilly is honored to receive this prestigious award alongside Dr. Hodes.”

The Charles A. Sanders, M.D., Partnership Award will be presented at a ceremony in October in Washington, D.C. For more information, please click here.

About the Foundation for the National Institutes of Health

The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit fnih.org.